VIKING THERAPEUTICS INC (VKTX) Fundamental Analysis & Valuation

NASDAQ:VKTX • US92686J1060

Current stock price

32.55 USD
+0.22 (+0.68%)
At close:
32.9499 USD
+0.4 (+1.23%)
After Hours:

This VKTX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. VKTX Profitability Analysis

1.1 Basic Checks

  • In the past year VKTX has reported negative net income.
  • VKTX had a negative operating cash flow in the past year.
  • In the past 5 years VKTX always reported negative net income.
  • In the past 5 years VKTX always reported negative operating cash flow.
VKTX Yearly Net Income VS EBIT VS OCF VS FCFVKTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -100M -200M -300M

1.2 Ratios

  • VKTX's Return On Assets of -50.25% is in line compared to the rest of the industry. VKTX outperforms 48.36% of its industry peers.
  • VKTX has a better Return On Equity (-56.28%) than 61.27% of its industry peers.
Industry RankSector Rank
ROA -50.25%
ROE -56.28%
ROIC N/A
ROA(3y)-28.55%
ROA(5y)-30.53%
ROE(3y)-31.14%
ROE(5y)-33.61%
ROIC(3y)N/A
ROIC(5y)N/A
VKTX Yearly ROA, ROE, ROICVKTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50 -100 -150

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for VKTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VKTX Yearly Profit, Operating, Gross MarginsVKTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. VKTX Health Analysis

2.1 Basic Checks

  • VKTX has more shares outstanding than it did 1 year ago.
  • VKTX has more shares outstanding than it did 5 years ago.
  • VKTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
VKTX Yearly Shares OutstandingVKTX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
VKTX Yearly Total Debt VS Total AssetsVKTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

2.2 Solvency

  • An Altman-Z score of 27.03 indicates that VKTX is not in any danger for bankruptcy at the moment.
  • VKTX has a Altman-Z score of 27.03. This is amongst the best in the industry. VKTX outperforms 92.10% of its industry peers.
  • There is no outstanding debt for VKTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 27.03
ROIC/WACCN/A
WACCN/A
VKTX Yearly LT Debt VS Equity VS FCFVKTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M 600M 800M

2.3 Liquidity

  • VKTX has a Current Ratio of 9.33. This indicates that VKTX is financially healthy and has no problem in meeting its short term obligations.
  • VKTX has a better Current ratio (9.33) than 79.00% of its industry peers.
  • VKTX has a Quick Ratio of 9.33. This indicates that VKTX is financially healthy and has no problem in meeting its short term obligations.
  • VKTX has a Quick ratio of 9.33. This is in the better half of the industry: VKTX outperforms 79.00% of its industry peers.
Industry RankSector Rank
Current Ratio 9.33
Quick Ratio 9.33
VKTX Yearly Current Assets VS Current LiabilitesVKTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. VKTX Growth Analysis

3.1 Past

  • VKTX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -218.00%.
EPS 1Y (TTM)-218%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-331.25%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 25.91% on average over the next years. This is a very strong growth
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-40.65%
EPS Next 2Y-22.85%
EPS Next 3Y-10.77%
EPS Next 5Y25.91%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
VKTX Yearly Revenue VS EstimatesVKTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 2033 1B 2B 3B 4B 5B
VKTX Yearly EPS VS EstimatesVKTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 10 20 30

More info and screens

Find the best growth stocksShow best growing peers

0

4. VKTX Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for VKTX. In the last year negative earnings were reported.
  • Also next year VKTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VKTX Price Earnings VS Forward Price EarningsVKTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VKTX Per share dataVKTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4

4.3 Compensation for Growth

  • VKTX's earnings are expected to decrease with -10.77% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-22.85%
EPS Next 3Y-10.77%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. VKTX Dividend Analysis

5.1 Amount

  • VKTX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

VKTX Fundamentals: All Metrics, Ratios and Statistics

VIKING THERAPEUTICS INC

NASDAQ:VKTX (3/23/2026, 8:23:25 PM)

After market: 32.9499 +0.4 (+1.23%)

32.55

+0.22 (+0.68%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-11
Earnings (Next)04-21
Inst Owners63.76%
Inst Owner Change-1.59%
Ins Owners2.22%
Ins Owner Change1.57%
Market Cap3.76B
Revenue(TTM)N/A
Net Income(TTM)-359.64M
Analysts85.83
Price Target95.46 (193.27%)
Short Float %21.65%
Short Ratio7.73
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-34.26%
Min EPS beat(2)-51.32%
Max EPS beat(2)-17.21%
EPS beat(4)0
Avg EPS beat(4)-29.95%
Min EPS beat(4)-51.32%
Max EPS beat(4)-17.21%
EPS beat(8)3
Avg EPS beat(8)-10.43%
EPS beat(12)5
Avg EPS beat(12)-6.84%
EPS beat(16)6
Avg EPS beat(16)-5.84%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.5%
PT rev (3m)0.36%
EPS NQ rev (1m)4.21%
EPS NQ rev (3m)-13.32%
EPS NY rev (1m)-17.79%
EPS NY rev (3m)-18.48%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-100%
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 5.89
P/tB 5.89
EV/EBITDA N/A
EPS(TTM)-3.18
EYN/A
EPS(NY)-4.47
Fwd EYN/A
FCF(TTM)-2.41
FCFYN/A
OCF(TTM)-2.41
OCFYN/A
SpS0
BVpS5.53
TBVpS5.53
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -50.25%
ROE -56.28%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-28.55%
ROA(5y)-30.53%
ROE(3y)-31.14%
ROE(5y)-33.61%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.33
Quick Ratio 9.33
Altman-Z 27.03
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-218%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-331.25%
EPS Next Y-40.65%
EPS Next 2Y-22.85%
EPS Next 3Y-10.77%
EPS Next 5Y25.91%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-160.63%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-57.58%
EBIT Next 3Y-20.98%
EBIT Next 5Y17%
FCF growth 1Y-217.44%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-217.44%
OCF growth 3YN/A
OCF growth 5YN/A

VIKING THERAPEUTICS INC / VKTX Fundamental Analysis FAQ

What is the ChartMill fundamental rating of VIKING THERAPEUTICS INC (VKTX) stock?

ChartMill assigns a fundamental rating of 3 / 10 to VKTX.


What is the valuation status of VIKING THERAPEUTICS INC (VKTX) stock?

ChartMill assigns a valuation rating of 0 / 10 to VIKING THERAPEUTICS INC (VKTX). This can be considered as Overvalued.


What is the profitability of VKTX stock?

VIKING THERAPEUTICS INC (VKTX) has a profitability rating of 1 / 10.


What is the expected EPS growth for VIKING THERAPEUTICS INC (VKTX) stock?

The Earnings per Share (EPS) of VIKING THERAPEUTICS INC (VKTX) is expected to decline by -40.65% in the next year.